Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Update

Allarity Therapeutics, Inc. (NASDAQ:ALLR) saw a significant decline in short interest in January. As of January 30th, there was short interest totaling 215,761 shares, a decline of 14.7% from the January 15th total of 253,018 shares. Currently, 1.3% of the shares of the stock are sold short. Based on an average daily volume of 129,627 shares, the days-to-cover ratio is currently 1.7 days. Based on an average daily volume of 129,627 shares, the days-to-cover ratio is currently 1.7 days. Currently, 1.3% of the shares of the stock are sold short.

Allarity Therapeutics Price Performance

ALLR stock opened at $0.85 on Tuesday. The business has a fifty day moving average price of $1.06 and a 200 day moving average price of $1.25. Allarity Therapeutics has a fifty-two week low of $0.61 and a fifty-two week high of $2.35. The stock has a market capitalization of $13.59 million, a price-to-earnings ratio of -1.43 and a beta of 0.23.

Allarity Therapeutics (NASDAQ:ALLR) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.04. On average, equities analysts expect that Allarity Therapeutics will post -78.08 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Private Advisor Group LLC bought a new stake in Allarity Therapeutics during the 3rd quarter worth about $441,000. Renaissance Technologies LLC raised its stake in shares of Allarity Therapeutics by 274.1% in the fourth quarter. Renaissance Technologies LLC now owns 247,612 shares of the company’s stock worth $267,000 after acquiring an additional 181,426 shares during the last quarter. DRW Securities LLC bought a new position in shares of Allarity Therapeutics in the fourth quarter worth about $133,000. Capital Advisors Inc. OK acquired a new position in shares of Allarity Therapeutics during the fourth quarter worth approximately $108,000. Finally, Citadel Advisors LLC bought a new stake in shares of Allarity Therapeutics during the third quarter valued at approximately $149,000. Institutional investors and hedge funds own 11.53% of the company’s stock.

Wall Street Analyst Weigh In

ALLR has been the subject of several analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Allarity Therapeutics in a research report on Wednesday, January 21st. Ascendiant Capital Markets lifted their price objective on Allarity Therapeutics from $9.25 to $9.50 and gave the company a “buy” rating in a report on Tuesday, December 9th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $9.50.

Allarity Therapeutics Company Profile

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.